Study on the Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis
- Substances:NavitoclaxRuxolitinib
Spain- Participants:18–64 years · 65+ years
- Substances:Navitoclax
Rare diseases
Investigational molecules
Locations
SpainStudy on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy
SpainStudy on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma
SpainStudy of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma
SpainStudy on Tirofiban and Aspirin for Patients with Acute Ischemic Stroke Due to Tandem Lesion
SpainStudy of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer
SpainStudy Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
SpainStudy of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer
SpainStudy Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib
SpainStudy on the Effects of Inebilizumab for Adults with Myasthenia Gravis
SpainStudy on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
SpainStudy on Niraparib for Maintenance Treatment in Patients with Advanced Ovarian Cancer After Initial Chemotherapy Response
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.